Quotient Sciences’ experts help you pinpoint the question you need to answer and identify the data you need to collect. Our M&S team have vast experience performing physiologically based pharmacokinetic (PBPK) modeling. We can provide a mechanistic understanding of the likely performance and disposition of your drug product (generic or new chemical entity [NCE]) in vivo and inform risk-based decisions on formulation and clinical design, ultimately reducing the cost of development.
The valuable role of M&S in drug development programs is being acknowledged through increasing inclusion in global regulatory submissions. We work collaboratively with you and can provide long-term support to your development programs, from drug discovery to lifecycle management.
Quotient Sciences’ Modeling and Simulation (M&S) team has recently completed qualification of GastroPlus, the software they use for physiologically based pharmacokinetic (PBPK) modeling. This 2-year project reflects Quotient Sciences’ commitment to conducting high-quality modeling work with regard to data integrity.
Our M&S activities span from early clinical development through to lifecycle management and are tailored to answer your specific needs. We offer services in either a standalone capacity or integrated with a clinical study conducted at Quotient Sciences that help you:
Dr. Alison Wilby is Director, Modeling and Simulation at Quotient Sciences. Dr. Wilby has over 20 years of experience in the pharmaceutical industry, working as part of big pharma organizations as well as the contract research sector.